SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

California Public Employees Retirement System increased its position in shares of United Therapeutic

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutra

The flights carried manufactured organs, being developed by United TherapeuticsThe flights are also

UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, ar

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

United Therapeutics is rated a Buy, driven by robust core business growth and a promising late-stage

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, tar

United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding it

United Therapeutics (UTHR) acquires Thymmune Therapeutics for $140M upfront, with up to $160M in mil

United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

Let us begin with a midyear summary of index results that might surprise you in light of the triple-

United Therapeutics received FDA approval for LungFX, a device designed to expand donor lung use in

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

While markets often view large-scale buyback authorizations as positives in and of themselves, autho

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Trans

While the latest stock market upsurge turned Micron (NASDAQ: MU) into a household name, Jim Simons m

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

United Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference

The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopat

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

U.S. stock futures down on Monday. Focus on Baidu, Brady, United Therapeutics for earnings. XP and R

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that f

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

United Therapeutics Corporation (NASDAQ:UTHR), a public benefit corporation, today announced that th

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Cataly

Through the collaboration, Varda and United Therapeutics will conduct pharmaceutical processing of s

Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

Wells Fargo analyst Benjamin Burnett upgrades United Therapeutics (NASDAQ:UTHR) from Equal-Weight

The formulation is being developed in collaboration with United Therapeutics Corporation United Ther

United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $5.82 per share which missed the an

An interim analysis of the PHINDER study identifies non-invasive measures that may facilitate earlie

Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Wei

HC Wainwright & Co. analyst Andrew S. Fein maintains United Therapeutics (NASDAQ:UTHR) with a

Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Equal-Wei

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutra

U.S. equity markets snap a five-week slide on Monday, bouncing off seven-month lows after President

Dow Jones index up 400 points. IQIYI rose on buyback & HK listing. CODI, UTHR, SGML, CLMT, TRON,

United Therapeutics (UTHR) stock surges 16% premarket after Tyvaso meets primary endpoint in pivotal

Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at be

TD Cowen analyst Joseph Thome maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises t